Severe gastritis due to pembrolizumab treatment in a lung cancer patient

Respirology Case Reports

Kyoichi Kaira¹  Hiroaki Ihara²  Noriko Hayama²  Yuichirou Honma²  Mitsuhiro Fujii²  Yukinari Itoigawa² 

[1] Department of Respiratory Medicine Comprehensive Cancer Center, International Medical Center, Saitama Medical University Saitama Japan;Department of Respiratory Medicine Koto Hospital Tokyo Japan;

关键词: Gastritis;    immune checkpoint inhibitors;    immune‐related adverse events;    inflammatory bowel disease;    pembrolizumab;   

DOI  :  10.1002/rcr2.636

来源: DOAJ

【 摘 要 】

Abstract Immune checkpoint inhibitors (ICIs) are known to induce gastrointestinal adverse events. Colitis occurs most frequently, and gastritis is less common. A few case reports of gastritis induced by ICIs have indicated that colitis induced by cytotoxic T‐lymphocyte antigen‐4 (CTLA‐4) resembles inflammatory bowel disease (IBD) and that programmed death‐1/programmed death ligand‐1 (PD‐1/PD‐L1) inhibitor can also induce the same type of colitis. We herein encountered a case of gastritis arising after 25 cycles of pembrolizumab administration in which the pathological and endoscopic findings resembled those of IBD. ICIs may induce gastritis in a manner similar to the pathogenesis of IBD.

【 授权许可】

Unknown